Özet:

Purpose: The aim of this study was to review the general characteristics of our patients with headache cancer, risk factors, methods of treatment and calculate their survival and evaluate the factors affecting survival and treatment results. Tools and Methods: Seventy-six patients diagnosed with BBK were assessed. The data of the study were obtained from the records of followed patients in the 2011-2020 years at the University of Sakarya Education and Research Hospital. Results: The average age at the moment of diagnosis was 62 ± 11.42 (December: 19-82) in all patients, including men 62, women 50. The most common settlement was larinks with a rate of 55%. The rates of smoking and alcohol consumption were 69% and 18% respectively. The secondary malignity rate was 18% and the most common was lung cancer (%9, n = 6). Patients were diagnosed at the stage 1,2,3 and 4, respectively, 13.45% (n = 9), 22.47% (n = 15), 50.77% (n = 34) and 11.93% (n = 8). In total, 42% of patients were metastatic, either at the moment of diagnosis or during follow-up. Metastasis areas were lungs in 13 patients (19,45) and lymphatic nodes in 10 patients (15%) and bones in 7 patients (10,56) and lymphatic nodes in 1 patient (1,50%) and lymphatic nodes in 1 patient (1,56). The local recurrence was 27% (n = 18). During the 1.2 and 3 58 stages, 50% of patients developed local recurrence and/or metastases. The majority of these patients were patients of stage 3 (n = 17 (59%)). The median non-sick survival in the stage 1-2 was 49 ± 29,65 months (December: 0-107 months), while the median non-sick survival in the stage 3 was 19 ± 10,95 months (December: 0-40 months). The metastatic first series post-chemotherapy median progressive survival was 8±3 months (December: 2-14 months) and the median overall survival in all patients was 192±83 months. The result: in our study, the rate of secondary malignity development was slightly high. The total doses of simultaneous radiotherapy sisplatin were slightly lower compared to similar other studies in literature. The most popular metastatic first-series chemotherapy combination was sisplatin/5Fluorourasil/setuximab. The results of unprogressive survival were slightly higher according to literature.

Anahtar Kelimeler: